Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Shanghai - Delayed Quote CNY

Jianmin Pharmaceutical Group Co.,Ltd. (600976.SS)

Compare
46.88
+1.03
+(2.25%)
At close: April 3 at 3:00:02 PM GMT+8
Loading Chart for 600976.SS
  • Previous Close 45.85
  • Open 45.32
  • Bid 46.87 x --
  • Ask 46.88 x --
  • Day's Range 45.32 - 46.97
  • 52 Week Range 39.75 - 66.80
  • Volume 1,962,659
  • Avg. Volume 1,825,393
  • Market Cap (intraday) 7.191B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 19.70
  • EPS (TTM) 2.38
  • Earnings Date --
  • Forward Dividend & Yield 1.20 (2.56%)
  • Ex-Dividend Date Apr 26, 2024
  • 1y Target Est --

Jianmin Pharmaceutical Group Co.,Ltd. manufactures and sells medicines in China. It offers medicines and pediatric drugs under the Jianmin, Longmu, and Yekaitai brand name. The company provides OTC, medical, and general health products, as well as consultation service. Jianmin Pharmaceutical Group Co.,Ltd. was founded in 1993 and is headquartered in Wuhan, China.

www.whjm.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 600976.SS

View More

Performance Overview: 600976.SS

Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

600976.SS
12.48%
SSE Composite Index (000001.SS)
0.29%

1-Year Return

600976.SS
17.42%
SSE Composite Index (000001.SS)
8.89%

3-Year Return

600976.SS
14.68%
SSE Composite Index (000001.SS)
1.81%

5-Year Return

600976.SS
225.36%
SSE Composite Index (000001.SS)
20.91%

Compare To: 600976.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 600976.SS

View More

Valuation Measures

Annual
As of 4/3/2025
  • Market Cap

    7.19B

  • Enterprise Value

    6.25B

  • Trailing P/E

    19.70

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.04

  • Price/Book (mrq)

    2.95

  • Enterprise Value/Revenue

    1.78

  • Enterprise Value/EBITDA

    13.99

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    10.33%

  • Return on Assets (ttm)

    2.98%

  • Return on Equity (ttm)

    15.63%

  • Revenue (ttm)

    3.5B

  • Net Income Avi to Common (ttm)

    362.18M

  • Diluted EPS (ttm)

    2.38

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.12B

  • Total Debt/Equity (mrq)

    7.17%

  • Levered Free Cash Flow (ttm)

    183.86M

Research Analysis: 600976.SS

View More

Company Insights: 600976.SS

Research Reports: 600976.SS

View More

People Also Watch